Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Name: Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
Published: 2025
License: Public Domain

Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

hepatocellular-carcinoma

resectable hepatocellular carcinoma with high risk of recurrence, hepatocellular carcinoma, neoadjuvant therapy, tace, atezolizumab, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Related documents